This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovasculardisease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Results CV event rates among patients treated with statins who have established CV disease, including coronary artery disease, cerebrovasculardisease, or peripheral arterial disease, accumulate over time, with a cumulative incidence of CV events reaching up to approximately 40% over 10 years.
Background and aims Epidemiology of atherosclerotic cardiovasculardisease might be different in patients with polygenic hypercholesterolemia plus high levels (≥30 mg/dl) of Lp(a) (H-Lpa) than in those with polygenic hypercholesterolemia alone (H-LDL). 3.17, P = 0.006). Occurrence of acute CAD was higher in H-Lpa men (HR 3.1,
Stroke, Volume 56, Issue Suppl_1 , Page ADP15-ADP15, February 1, 2025. Background:White matter hyperintensities (WMH) of presumed vascular origin can be associated with vascular cognitive impairment and dementia. However, WMH are also seen in asymptomatic subjects. FLAIR/T1 images were segmented to create WMH masks.
Stroke, Volume 55, Issue Suppl_1 , Page ATMP102-ATMP102, February 1, 2024. Introduction:Lipoprotein(a) [Lp(a)] is a known risk factor for cardiovasculardisease; however, its association with cerebrovasculardisease is not as well established.Methods:Data from HCHS/SOL, a population-based cohort of Hispanics/Latinos, was utilized.
Stroke, Volume 55, Issue Suppl_1 , Page ATP271-ATP271, February 1, 2024. Introduction:Despite significant efforts to increase public awareness of cerebrovasculardisease, the incidence of stroke and transient ischemic attack (TIA) in young adults has remained elevated, representing a major public health concern.
Stroke, Volume 56, Issue Suppl_1 , Page ATP110-ATP110, February 1, 2025. Introduction:Cardiovascular comorbidities are highly prevalent in patients who suffer from cerebrovasculardisease. Peak oxygen uptake (VO2peak) is a well-established, independent predictor of cardiovascular health and premature mortality.
According to WHO , cardiovasculardiseases are the leading cause of death worldwide – it is estimated that they are the cause of 17.9 Cardiovasculardiseases are a group of diseases of the heart and blood vessels. They include coronary artery disease, cerebrovasculardisease, and rheumatic heart disease.
They increase the risk of hypertension, coronary artery disease, coronary vasospasm, arrhythmias, cardiomyopathy, cardiac arrest, and stroke. decline in overall CVD mortality rates (Table). Stratifying by drug type, methamphetamine-involved CVD death rates increased by 14.9% AAPC, compared to a 3.1%
Cardiovasculardiseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, cerebrovasculardisease (e.g., stroke), peripheral arterial disease, congenital heart anomalies, deep vein thrombosis, and pulmonary embolism.
History of Cardiovasculardisease (all studies): Especially any history of heart failure or structural cardiac disease, including valvular 4. Negative predictors included dementia, pacemaker, coronary revascularization, and cerebrovasculardisease. to 1.45) for fatal or nonfatal stroke. to 3.80).
ObjectiveThis meta-analysis aims to evaluate the safety and efficacy of indobufen in the treatment of cardiovasculardiseases, cerebrovasculardiseases, and thromboembolic disorders. The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content